{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T13:57:01Z","timestamp":1772287021262,"version":"3.50.1"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,4,15]]},"DOI":"10.2169\/internalmedicine.1893-23","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T22:44:46Z","timestamp":1694126686000},"page":"1061-1066","source":"Crossref","is-referenced-by-count":13,"title":["Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study"],"prefix":"10.2169","volume":"63","author":[{"given":"Shohei","family":"Okusa","sequence":"first","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munenori","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[{"name":"Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14: 1023-1036, 2015.","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96: 114-122, 2021.","DOI":"10.1212\/WNL.0000000000011124"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs 78: 367-376, 2018.","DOI":"10.1007\/s40265-018-0875-9"},{"key":"4","unstructured":"4. U.S. Food &amp; Drug Administration. FDA Adverse Event Reporting System (FAERS) quarterly data extract files [Internet]. [cited 2022 Apr 20]. Available from: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chuma M, Nakamoto A, Bando T, et al. Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis. Clin Infect Dis 75: 1416-1422, 2022.","DOI":"10.1093\/cid\/ciac128"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wei C, Liu Y, Jiang A, Wu B. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. Int J Clin Pharm 44: 709-716, 2022.","DOI":"10.1007\/s11096-022-01397-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wu B, Hu Q, Tian F, Wu F, Li Y, Xu T. A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep 11: 10709, 2021.","DOI":"10.1038\/s41598-021-90108-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13: 519-523, 2004.","DOI":"10.1002\/pds.1001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54: 315-321, 1998.","DOI":"10.1007\/s002280050466"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11: 3-10, 2002.","DOI":"10.1002\/pds.668"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hollingshead S, Tang CM. An overview of <i>Neisseria meningitidis<\/i>. Methods Mol Biol 1969: 1-16, 2019.","DOI":"10.1007\/978-1-4939-9202-7_1"},{"key":"12","unstructured":"12. Howard JF Jr, Utsugisawa K, Benatar M, et al.; the REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16: 976-986, 2017."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. 14: 17562864211001995, 2021.","DOI":"10.1177\/17562864211001995"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Raabe VN, Shane AL. Group B <i>Streptococcus<\/i> (<i>Streptococcus agalactiae<\/i>). Microbiol Spectr 7: GPP3-0007-2018, 2019.","DOI":"10.1128\/microbiolspec.GPP3-0007-2018"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kothari NJ, Morin CA, Glennen A, et al. Invasive group B streptococcal disease in the elderly, Minnesota, USA, 2003-2007. Emerg Infect Dis 15: 1279-1281, 2009.","DOI":"10.3201\/eid1508.081381"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Giussani S, Pietrocola G, Donnarumma D, et al. The Streptococcus agalactiae complement interfering protein combines multiple complement-inhibitory mechanisms by interacting with both C4 and C3 ligands. FASEB J 33: 4448-4457, 2019.","DOI":"10.1096\/fj.201801991R"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/8\/63_1893-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T03:30:55Z","timestamp":1713583855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/8\/63_1893-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1893-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"article-number":"1893-23"}}